Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals, Inc. (SUPN)
Price$43.89Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $719.0M | $661.8M | $607.5M | $667.2M | $579.8M | $520.4M | $392.8M | $408.9M | $302.2M | $215.0M | $147.5M | $92.7M | $12.0M | $1.5M | $803,000 | $106,000 |
| Gross profit | $644.4M | $583.9M | $523.7M | $580.0M | $504.7M | $467.9M | $376.1M | $393.5M | $287.0M | $203.0M | $139.0M | $86.9M | $10.9M | — | — | — |
| Gross margin | 89.63% | 88.23% | 86.21% | 86.93% | 87.05% | 89.92% | 95.76% | 96.24% | 94.97% | 94.43% | 94.29% | 93.79% | 90.81% | — | — | — |
| Research & development | $106.2M | $108.8M | $91.6M | $74.6M | $90.5M | $76.0M | $69.1M | $89.2M | $49.6M | $42.8M | $29.1M | $19.6M | $17.2M | $23.5M | $30.6M | $35.1M |
| Operating expenses | $781.2M | $580.2M | $612.8M | $621.1M | $493.7M | $346.7M | $244.2M | $264.5M | $202.7M | $160.8M | $126.6M | $98.0M | $73.9M | $43.6M | $38.6M | $40.2M |
| Operating income | −$62.3M | $81.7M | −$5.3M | $46.1M | $86.0M | $173.7M | $148.6M | $144.4M | $99.5M | $54.2M | $20.8M | −$5.3M | −$61.9M | −$42.2M | −$37.8M | −$40.1M |
| Operating margin | −8.66% | 12.34% | −0.87% | 6.91% | 14.84% | 33.38% | 37.83% | 35.33% | 32.93% | 25.22% | 14.13% | −5.69% | −515.18% | −2,849.26% | −4,701.37% | −37,851.89% |
| EBITDA | $29.3M | $162.1M | $79.6M | $131.7M | $118.6M | $191.8M | $155.2M | $151.5M | $107.7M | $56.6M | $21.8M | −$4.3M | −$61.2M | −$41.3M | −$36.9M | −$38.9M |
| EBITDA margin | 4.07% | 24.49% | 13.10% | 19.73% | 20.46% | 36.86% | 39.52% | 37.05% | 35.63% | 26.33% | 14.76% | −4.69% | −509.01% | −2,790.41% | −4,591.91% | −36,731.13% |
| Net income | −$38.5M | $73.9M | $1.3M | $60.7M | $53.4M | $127.0M | $113.1M | $111.0M | $57.3M | $91.2M | $13.9M | −$10.9M | −$92.3M | −$46.3M | $53.8M | −$38.5M |
| Net profit margin | −5.36% | 11.16% | 0.22% | 9.10% | 9.21% | 24.39% | 28.79% | 27.14% | 18.95% | 42.43% | 9.46% | −11.79% | −767.73% | −3,127.30% | 6,701.74% | −36,285.85% |
| Basic EPSper basic share | -$0.68 | $1.34 | $0.02 | $1.13 | $1.01 | $2.41 | $2.16 | $2.13 | $1.13 | $1.84 | $0.29 | -$0.26 | -$2.90 | -$2.72 | $31.39 | -$26.38 |
| Diluted EPSper diluted share | -$0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 | $0.28 | -$0.26 | -$2.90 | -$2.72 | $31.39 | -$26.38 |
Owners
Reported shareholders
16.08%of listed shares
BlackRock, Inc.9.35M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 16.08%9.35M shares |
MILLENNIUM MANAGEMENT LLC | 6.62%3.85M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 5.68%3.31M shares |
Khattar Jack A. | ≈5.43%3.16M shares |
ARMISTICE CAPITAL, LLC | 4.55%2.65M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.33%2.52M shares |
STATE STREET CORP | 4.23%2.46M shares |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 4.09%2.38M shares |
DIMENSIONAL FUND ADVISORS LP | 3.57%2.08M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.70%1.57M shares |
Stephens Investment Management Group LLC | 2.55%1.49M shares |
RENAISSANCE TECHNOLOGIES LLC | 2.54%1.48M shares |
LOOMIS SAYLES & CO L P | 2.54%1.48M shares |
CITADEL ADVISORS LLC | 2.36%1.37M shares |
TWO SIGMA INVESTMENTS, LP | 2.04%1.18M shares |
GW&K Investment Management, LLC | 1.78%1.04M shares |
Sofinnova Investments, Inc. | 1.78%1.04M shares |
Qube Research & Technologies Ltd | 1.59%922.17K shares |
MORGAN STANLEY | 1.51%876.84K shares |
GOLDMAN SACHS GROUP INC | 1.41%819.43K shares |
Percentages use 58.16M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 18, 2026Form 4 · 10b5-1 | Bhatt Padmanabh P.Sr. VP of IP, CSO | SellCommon Stock | 412 | $50.48 | $20.8K | 17.0K |
| Mar 18, 2026Form 4 · 10b5-1 | Bhatt Padmanabh P.Sr. VP of IP, CSO | SellCommon Stock | 6.8K | $49.55 | $338.8K | 17.5K |
| Mar 17, 2026Form 4 · 10b5-1 | Bhatt Padmanabh P.Sr. VP of IP, CSO | SellCommon Stock | 22.3K | $50.73 | $1.13M | 17.0K |
| Mar 17, 2026Form 4 · 10b5-1 | Bhatt Padmanabh P.Sr. VP of IP, CSO | SellCommon Stock | 27.7K | $49.95 | $1.38M | 39.3K |
| Mar 16, 2026Form 4 · 10b5-1 | Bhatt Padmanabh P.Sr. VP of IP, CSO | SellCommon Stock | 15.9K | $50.49 | $802.1K | 17.0K |